Market Place

Market Place

Market Place

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search
All
API
FDF
Price
Services
Excipients
Enquiries

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Price
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    Scorr-Insert
    X

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    A collaboration with SCORR Marketing

    Loading...

    All Data

    Filters Filter refresh
    ×
    FILTER DATA :
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            Upfront Payment filter
              refresh

              Product Type Full Screen

              Companies Full Screen

              Zambon Group SpA

              • Development Update

              Virtual BoothCommitted to providing Highly Customized Solutions for all your Development Programs.

              ITALY Italy

              Contact Supplier Contact Supplier

              Virtual Booth Virtual Booth

              BIO International Convention

              Participation Not Confirmed

              Update your events

              A new FDA Fast Track designation for Zambon

              Contact the Supplier

              Lead Product(s): Cyclosporin A

              Therapeutic Area: Pulmonary/Respiratory Diseases

              Highest Development Status: Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable April 28, 2020

              Details:

              FDA has granted Fast Track designation to Liposomal Cyclosporine A for Inhalation (L‑CsA‑i), in late-stage clinical development for the treatment of Bronchiolitis Obliterans Syndrome.

              Zambon Group SpA

              • Development Update

              Virtual BoothCommitted to providing Highly Customized Solutions for all your Development Programs.

              ITALY Italy

              Contact Supplier Contact Supplier

              Virtual Booth Virtual Booth

              BIO International Convention

              Participation Not Confirmed

              Update your events

              Breath Therapeutics initiates BOSTON-3 and BOSTON-4 for the treatment of bronchiolitis obliterans syndrome

              Contact the Supplier

              Lead Product(s): Cyclosporin A

              Therapeutic Area: Pulmonary/Respiratory Diseases

              Highest Development Status: Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable February 20, 2020

              Details:

              Liposomal Cyclosporine A for Inhalation (L?CsA?i) is advancing in clinical studies for the treatment for bronchiolitis obliterans syndrome.

              PharmaCompass__DigitalAd